Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 3/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8880590 | 0.83 | PDGFRB (0.39) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL30451572 | 0.83 | PDGFRB (0.39) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL20528292 | 0.76 | BACE1 (0.47) | DYRK1AHTTKDM4EALDH1A1CYP2A6 | |
| SCHEMBL276487 | 0.75 | DYRK1A (0.41) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL31440863 | 0.75 | CYP1A2 (0.59) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL24223152 | 0.75 | DYRK1A (0.41) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL1561156 | 0.75 | EGFR (0.55) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL2619270 | 0.75 | CYP1A2 (0.59) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL276488 | 0.75 | DYRK1A (0.61) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB | |
| SCHEMBL2012829 | 0.75 | DYRK1A (0.41) | DYRK1ACSNK1DCSNK1ECLK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| CN-117279896-A | Amino substituted pyrido ring compounds, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022214044-A1 | AMINE-SUBSTITUTED PYRIDINE FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-10-13 | — | — | WO | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) | 2021-10-19 | — | — | US | disclosed |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-23 | — | — | US | disclosed |
| EP-3638672-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-22 | — | — | EP | disclosed |
| CN-110753692-A | Chemical compounds as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2018229629-A1 | CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | WO | disclosed |
| EP-2662353-A2 | Antibacterial agents | Achaogen, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20060148730-A1 | Using macrolide and ketolide compound | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-07-06 | — | — | US | disclosed |
| US-20050014706-A1 | Method of treating tuberculosis | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2005-01-20 | — | — | US | disclosed |
| EP-1345953-A2 | KETOLIDE ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6590083-B1 | Compounds of given formula; erythromycin derivatives; useful in the treatment of bacterial and protozoal infections and conditions involving gastric motility | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-08 | — | — | US | disclosed |
| US-20030004165-A1 | Polyazanaphthalene compounds and pharmaceutical use thereof | AJINOMOTO CO. INC (JP) | 2003-01-02 | — | — | US | disclosed |
| WO-2002032918-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149035-B2 | Chemical compounds as H—PGDS inhibitors | HPGDS, PTGS1, PTGIS | DYRK1A 3703/4885CSNK1D 882/4885CSNK1E 2159/4885 |
| US-20060148730-A1 | Using macrolide and ketolide compound | MLYCD, TREH, TKT | DYRK1A 4586/4885CSNK1D 872/4885CSNK1E 1680/4885 |
| US-20200123152-A1 | Chemical Compounds as H-PGDS Inhibitors | HPGDS, PTGS1, PTGIS | DYRK1A 3659/4885CSNK1D 868/4885CSNK1E 2088/4885 |
| US-20030004165-A1 | Polyazanaphthalene compounds and pharmaceutical use thereof | MMP1, TNF, MMP12 | DYRK1A 4361/4885CSNK1D 4226/4885CSNK1E 3854/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | DYRK1A 3852/4885CSNK1D 2163/4885CSNK1E 2378/4885 |
| US-20050014706-A1 | Method of treating tuberculosis | TREH, TKT, DCXR | DYRK1A 4521/4885CSNK1D 1377/4885CSNK1E 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.